MASTDISCS AST. Leading the field with a complete solution for AST and Identification disc testing. Comprehensive range. Premium quality products
|
|
|
- Madeline Small
- 6 years ago
- Views:
Transcription
1 IVD solutions through partnership MASTDISCS AST Leading the field with a complete solution for AST and Identification disc testing Comprehensive range Premium quality products Compatible with EUCAST and CLSI standards Bespoke service available
2 MAST has been a manufacturer of antibiotic susceptibility test products since 1957, and continues to be at the forefront of developments in this field. With an ever-expanding portfolio of antibiotic susceptibility, combination and identification discs, MAST supplies the most comprehensive range available worldwide. MAST also offers a range of services including mastpharma development and mastpharma stability for the evaluation of novel antimicrobial compounds for the pharmaceutical industry. Disc diffusion is still the most popular method for determining bacterial antibiotic susceptibility in the treatment of infectious disease, as highlighted by the variety of international standardised procedures including The European Committee on Antimicrobial Susceptibility Testing (EUCAST), The Clinical and Laboratory Standards Institute (CLSI) and The British Society for Antimicrobial Chemotherapy (BSAC). From January 2016 BSAC guidelines were superseded by EUCAST. MAST continues to support laboratories with the supply of BSAC concentrations until January MASTDISCS are available as an extensive range of test discs presented in dispensing cartridges or vials, with quality assurance guaranteed in accordance to standardised test protocols as issued by the above national and international organisations. Disc Diffusion Susceptibility Testing Order No Product Packsize MASTDISCS - ANTIBIOTIC SUSCEPTIBILITY DISCS IN CARTRIDGES AND VIALS in Cartridges (5 50 discs per pack) STOCKCART Stock Susceptibility Cartridge Discs of a single type 1 pack FUNGCART Stock Antifungal Cartridge Discs of a single type 1 pack SPECIALCART Cartridge Discs made to special order* Min 18 packs VOLCART Cartridge Discs made to special order* Min 98 packs MASTDISCS (100 discs per vial) STOCKDISC Stock Susceptibility Discs of a single type 1 vial FUNGDISC Stock Antifungal Discs of a single type 1 pack SPECIALDISC Discs made to special order* Min 22 packs VOLDISC Discs made to special order* Min 97 packs TOOL/C *Set up charge for Special Discs in vials or cartridges per new A one off charge for customisation of each new specification specification 2
3 ANTIBIOTIC SUSCEPTIBILITY DISCS IN CARTRIDGES - STOCK RANGE Cartridges (unless otherwise stated) BSAC EUCAST CLSI 5 50 discs Amikacin AK 30C Amoxicillin A 2C Amoxicillin A 10C Amoxicillin A 25C Ampicillin AP 2C Ampicillin AP 10C Ampicillin AP 25C Ampicillin/Sulbactam SAM 20C Amoxicillin/clavulanic acid AUG 3C Amoxicillin/clavulanic acid AUG 30C Azithromycin ATH 15C Aztreonam ATM 30C Bacitracin 10 units BA 10C Cefaclor CFC 30C Ceftibuten CFB 30C Cefamandole CMD 30C Cefadroxil CDX 30C Cefepime CPM 30C Cefixime CFM 5C Cefoperazone CPZ 30C Cefotaxime CTX 5C Cefotaxime CTX 30C Cefoxitin FOX 10C Cefoxitin FOX 30C Cefpodoxime CPD 10C Ceftaroline CPT 5C Ceftaroline CPT 30C Ceftazidime/avibactam 10-4* CZA 14C Ceftazidime/avibactam CZA 50C Ceftazidime CAZ 10C Ceftazidime CAZ 30C Ceftriaxone CRO 5C Ceftriaxone CRO 30C Ceftolozane/tazobactam C/T 40C Cefuroxime CXM 5C Cefalexin CFX 30C Cefradine CRD 30C Cefuroxime CXM 30C Cephalothin KF 30C Cephazolin CZ 30C Chloramphenicol C 10C Chloramphenicol C 30C Ciprofloxacin CIP 1C Ciprofloxacin CIP 5C Clarithromycin CLA 2C Clarithromycin CLA 5C Clarithromycin CLA 15C Clindamycin CD 2C Doripenem DOR 10C Doxycycline DXT 30C Enrofloxacin ENF 5C Ertapenem ETP 10C Erythromycin E 5C Erythromycin E 15C Florfenicol FFC 30C Fosfomycin 200/ Glucose-6-Phosphate FOT 200C Fusidic Acid FC 10C Gentamicin GM 10C 3
4 ANTIBIOTIC SUSCEPTIBILITY DISCS IN CARTRIDGES - STOCK RANGE Cartridges (unless otherwise stated) BSAC EUCAST CLSI 5 50 discs Gentamicin GM 30C Gentamicin GM 120C Gentamicin GM 200C Imipenem IMI 10C Kanamycin K 30C Levofloxacin LEV 1C Levofloxacin LEV 5C Linezolid LZD 10C Linezolid LZD 30C Mecillinam MEC 10C Meropenem MEM 10C Metronidazole MZ 2.5C Metronidazole MZ 5C Minocycline MN 30C Moxifloxacin MFX 1C Moxifloxacin MFX 5C Mupirocin MUP 5C Mupirocin MUP 20C Mupirocin MUP 200C Nalidixic Acid NA 30C Neomycin NE 10C Neomycin NE 30C Netilmicin NET 10C Netilmicin NET 30C Nitrofurantoin NI 100C Nitrofurantoin NI 200C Nitrofurantoin NI 300C Nitroxoline NIB30C Norfloxacin NOR 2C Norfloxacin NOR 10C Novobiocin NO 5C Ofloxacin OFX 5C Oxacillin OX 1C Pefloxacin PEF 5C Penicillin G 1 unit PG 1C Penicillin G 10 units PG10C Piperacillin PRL 30C Piperacillin PRL 75C Piperacillin PRL 100C Piperacillin/tazobactam PTZ 36C Piperacillin/tazobactam PTZ 85C Piperacillin/tazobactam PTZ 110C Polymyxin B 300 units PB 300C Quinupristin/dalfopristin SYN 15C Rifampicin RP 2C Rifampicin RP 5C Spectinomycin SPC 25C Streptomycin S 10C Streptomycin S 300C Teicoplanin TEC 30C Temocillin TEM 30C Tetracycline T 10C Tetracycline T 30C Ticarcillin TC 75C Tigecycline TGC 15C Ticarcillin/clavulanic acid TIM 85C Tobramycin TN 10C Trimethoprim TM 2.5C 4
5 ANTIBIOTIC SUSCEPTIBILITY DISCS IN CARTRIDGES - STOCK RANGE Cartridges (unless otherwise stated) BSAC EUCAST CLSI 5 50 discs Trimethoprim TM 5C Trimethoprim/sulfamethoxazole 1.25/ TS 25C Vancomycin VA 5C Vancomycin VA 30C Blank discs BD0680W/C SPECIALIST VETERINARY SUSCEPTIBILITY DISCS Description Order Code Cartridges Vials (unless otherwise stated) 5 50 discs 100 discs Cefquinome 30 CEQ30C/NCE - Gamithromycin 15 GAM15C/NCE - Marbofloxacin 5 MAR5C/NCE - Pradofloxacin 5 PRA5C/NCE - Tidlipirison 60 TIP60C/NCE - Tylosin 30 TY30C/NCE TY30/NCE ANTIBIOTIC SUSCEPTIBILITY DISCS IN VIALS - STOCK RANGE Vials (unless otherwise stated) BSAC EUCAST CLSI 100 discs Amikacin AK30 Bacitracin 8 units BA8 Bacitracin 10 units BA10 Cefpodoxime CPD10 Chloramphenicol C10 Chloramphenicol C30 Gentamicin GM10 Imipenem IMI10 Meropenem MEM 10 Metronidazole MZ 2.5 Metronidazole MZ 5 Nalidixic Acid NA 30 Novobiocin NO 5 Oxacillin OX 1 Penicillin G 1 unit PG 1 Penicillin G 2 units PG 2 Vancomycin VA 5 Blank discs BD0638W SELECT RANGE OF ANTIBIOTIC SUCSCEPTIBILITY DISCS IN CARTRIDGES - STOCK RANGE Cartridges (unless otherwise stated) BSAC EUCAST CLSI 5 50 discs Carbenicillin PY100C Telithromycin TEL15C 5
6 Order No Product Mechanism Packsize (tests) ANTIFUNGAL SUSCEPTIBILITY DISCS IN CARTRIDGES AND VIALS - STOCK RANGE Description Order Code Cartridges Vials (unless otherwise stated) 5 50 discs 100 discs Amphotericin B 20 AMB 20C - Clotrimazole 10 CTM 10C - Econazole 10 ECN 10C - Fluconazole 10 FCN 10C - Fluconazole 25 FCN 25C FCN 25 Flucytosine 1 FY 1C - Ketoconazole 10 KCA 10C - Miconazole 10 MCL 10C - Nystatin 100 NY 100C - MASTDISCS Combi COMBINATION DISC SETS FOR THE DETECTION OF ANTIBIOTIC RESISTANCE D52C Extended Spectrum ß Lactamase Set ESßL 50 tests D62C Cefotaxime 30 & Cefotaxime 30/Clavulanic Acid 10 ESßL 150 tests D63C Cefepime 30 & Cefepime 30/Clavulanic Acid 10 ESßL 150 tests D64C Ceftazidime 30 & Ceftazidime 30/Clavulanic Acid 10 ESßL 150 tests D66C Cefpodoxime 10 & Cefpodoxime 10/Clavulanic Acid 1 ESßL 150 tests D67C Extended Spectrum ß Lactamase Set (CPD10) ESßL 50 tests D68C AmpC & ESBL Detection Set AmpC/ESßL 50 tests D69C AmpC Detection Set AmpC 50 tests D72C AmpC, ESBL & Carbapenemase Detection Kit AmpC/ESßL/Carbapenemases 50 tests D73C MAST Carba plus MBL/KPC/OXA 50 tests Additional carbapenemase screening and identification tests D74 MAST ICT A screening test for the detection of carbapenemase 25 tests production in Enterobacteriaceae, Pseudomonas and Acinetobacter spp. D71C MAST CAT-ID - For presumptive identification of Carbapenemase production 250 tests TEM30C To aid presumptive identification of OXA-48 5 x 50 discs 6
7 Order No Product Mechanism Packsize (tests) LOW STRENGTH PENICILLIN DISCS For detecting the emergence of penicillin resistance. (vials of 100 discs or 5 50 discs in cartridges) PG1 Penicillin G (vials) 1 unit 1 vial PG1C Penicillin G (cartridges) 1 unit 1 pack The following discs are available to special order and subject to 6 weeks lead time. PG0.03 Penicillin G (vials) 0.03 unit Min order 22 vials HIGH STRENGTH AMINOGLYCOSIDE DISCS The following discs are available to special order and subject to 6 weeks lead time. For detecting high level aminoglycoside resistance. (vials of 100 discs or 5 50 discs in cartridges) GM500C Gentamicin (cartridges) 500µg Min order K1000C Kanamycin (cartridges) 1000µg 18 packs K1000 Kanamycin (vials) 1000µg Min order 22 vials 7
8 Order No Product Packsize DISCMASTER DISPENSER Robust and reliable antimicrobial cartridge disc dispensers designed for use with MASTDISCS Antimicrobial Susceptibility Test Cartridges. DISCMASTER Dispenser - 6 place (contact MAST for the product code of the latest model) 1 SILICA63 Silica Gel Capsule for DISCMASTER 6 place Dispenser 4 CANISTER Canister for DISCMASTER 6 place Dispenser 1 MDD16 DISCMASTER 16 Dispenser - 16 place 1 SILICA16 Silica Gel Capsule for DISCMASTER 16 Dispenser (MDD16) 2 v 4.0 CEA 0118 United Kingdom Mast Group Ltd. Mast House Derby Road, Bootle Merseyside L20 1EA Tel: + 44 (0) Fax: + 44 (0) sales@mastgrp.com Germany Mast Diagnostica GmbH Feldstrasse 20 DE Reinfeld Tel: + 49 (0) Fax: + 49 (0) mast@mast-diagnostica.de France Mast Diagnostic 12 Rue Jean-Jacques Mention CS Amiens CEDEX 1 Tél (0) Fax + 33 (0) info@mast-diagnostic.fr
EUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...
SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* The next-generation MicroScan WalkAway System combines proven technology and reliability with enhanced ease-of-use features to streamline
European Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
Routine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
Compliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
AMR Industry Alliance Antibiotic Discharge Targets
AMR Industry Alliance Antibiotic Discharge Targets List of Predicted No-Effect Concentrations (PNECs) The members of the AMR Industry Alliance have developed a unified approach to establishing discharge
European Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
Compliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
Product Catalogue 2017 Clinical and Industrial Microbiology
Antibiotic discs in cartridge Description µg CLSI 1,2 EUCAST 3,4 BSAC Packaging * Ref. Amikacin AK x0 Discs 9004 Amoxicillin AML 2 x0 Discs 911 Amoxicillin AML x0 Discs 9133 Amoxicillin AML 2 x0 Discs
What s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
Product Catalogue 2016 Clinical and Industrial Microbiology
Antibiotic discs in cartridge Description μg CLSI 1,2 EUCAST 3,4 BSAC Packaging * Ref. Amikacin AK x0 Discs 9004 Amoxicillin AML 2 x0 Discs 911 Amoxicillin AML x0 Discs 9133 Amoxicillin AML 2 x0 Discs
2 New products for 2014
2 New products for 2014 Group B Streptococci Testing Thermo Scientific Brilliance GBS Agar Thermo Scientific TM Brilliance GBS Agar is a clear, selective chromogenic medium for the presumptive identification
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
EUCAST-and CLSI potency NEO-SENSITABS
EUCASTand CLSI potency NEOSENSITABS Neo Sensitabs Page 1 / 6 Document: 6.2.0 Fastidious organisms EUCAST Interpretation zones and MIC breakpoints according to recommendations by the "Comité de l'antibiogramme
Performance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
Antimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
MicroScan Microbiology Systems MORE CHOICES MORE ANSWERS. MicroScan GRAM NEGATIVE AND GRAM POSITIVE PANELS
MicroScan Microbiology Systems MORE CHOICES MORE ANSWERS MicroScan GRAM NEGATIVE AND GRAM POSITIVE PANELS LABORATORIES ON THE FRONT LINE From the National Action Plan for Combating Antibiotic Resistant
a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
British Society for Antimicrobial Chemotherapy
British Society for Antimicrobial Chemotherapy BSAC to actively support the EUCAST Disc Diffusion Method for Antimicrobial Susceptibility Testing in preference to the current BSAC Disc Diffusion Method
Introduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience.
Secondary Care Data Validation: What do commissioners need to know? Stuart Brown Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England March 2014 Introduction Antimicrobial
Brief reports. Heat stability of the antimicrobial activity of sixty-two antibacterial agents
Journal of Antimicrobial Chemotherapy (5) 35, -5 Brief reports Heat stability of the antimicrobial activity of sixty-two antibacterial agents Walter H. Traub and Birgit Leonhard Institut fur Medizinische
21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review
(1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of
January 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
January 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
British Society for Antimicrobial Chemotherapy
British Society for Antimicrobial Chemotherapy Standing Committee on Susceptibility Testing Version 13.0, 10-06-2014 Content Page Additional information Changes in version 13 2 Suggestions for appropriate
Antimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
Intrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
- the details, where possible, of the antibiotic products these companies supply or have supplied.
Under the Freedom of Information Act 2000 please could you provide me with a list of all companies currently supplying antibiotics - or that have supplied antibiotics in the last three years - to Royal
I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Antibiotics.
Ref: FOI/CAD/ID 3459 27 June 2017 Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone Kent ME16 9QQ Email: mtw-tr.foiadmin@nhs.net Freedom of Information Act
BSAC standardized disc susceptibility testing method (version 8)
Journal of Antimicrobial Chemotherapy (2009) 64, 454 489 doi:10.1093/jac/dkp244 Advance Access publication 8 July 2009 BSAC standardized disc susceptibility testing method (version 8) J. M. Andrews* for
Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland,
Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, 2008-2016 Alicia Russell Federation of Infection Societies conference 14 th November 2018 alisia_russell BSAC
Penicillins - EUCAST clinical MIC breakpoints (version 1.3)
EUCAST clinical MIC breakpoints - penicillins Penicillins - EUCAST clinical MIC breakpoints 2009-04-19 (version 1.3) Penicillins Click on antibiotic name to see wild type MIC distributions. Enterobacteriaceae
Antimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
ESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #116 (NQF 0058): Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
Antimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia
EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia Background The Expert Advisory Group on Antimicrobial Resistance of the NH&MRC provides advice to Australian governments and
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
What is new in 2011: Methods and breakpoints in relation to subcommittees and expert groups. by author. Gunnar Kahlmeter, Derek Brown
What is new in 2011: Methods and breakpoints in relation to subcommittees and expert groups Gunnar Kahlmeter, Derek Brown Izmir, February 2011 Anaerobes subcommittee EUCAST Subcommittee on breakpoints
1 INTRODUCTION OBJECTIVES OUTLINE OF THE SALM/CAMP EQAS
PROTOCOL For antimicrobial susceptibility testing of Salmonella, Campylobacter and optional genotypic characterisation of AmpC-, ESBL- and carbapenemase-producing test strains 1 INTRODUCTION... 1 2 OBJECTIVES...
2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
Main objectives of the EURL EQAS s
EQAS Enterococci, Staphylococci and E. coli EURL workshop, April, 11 Lourdes García Migura Main objectives of the EURL EQAS s To improve the comparability of antimicrobial susceptibility testing (AST)
Streptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance
Streptococcus pneumoniae Oxacillin µg as screen for beta-lactam resistance Version 6. June Streptococcus pneumoniae and zone diameter correlates The following histograms present inhibition zone diameter
Concise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
Taiwan Surveillance of Antimicrobial Resistance (TSAR)
Taiwan Surveillance of Antimicrobial Resistance (TSAR) 2009 MIRL Symposium July 17, 2009 Tsai-Ling Yang Lauderdale ( ) Microbial Infections Reference Laboratory (MIRL) Division of Infectious Diseases,
Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes
Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes Prof C. Wattal Hon. Sr. Consultant & Chairman Dept. of Clinical Microbiology Sir Ganga Ram Hospital New Delhi
ESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL
ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance
Measuring Antibiotic Use in NHSN
Measuring Antibiotic Use in NHSN Jonathan R. Edwards, MStat. Research Mathematical Statistician Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious Diseases SHEA
MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
Childrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
CONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
Lab Exercise: Antibiotics- Evaluation using Kirby Bauer method.
Lab Exercise: Antibiotics- Evaluation using Kirby Bauer method. OBJECTIVES 1. Compare the antimicrobial capabilities of different antibiotics. 2. Compare effectiveness of with different types of bacteria.
REVOLUTIONARY. MMinimum. BBiofilm EEradication Concentration. inimizing WE HAVE FOUND THE ANSWER.
REVOLUTIONARY. Are recurrent bacterial infections a frustration in your practice? WE HAVE FOUND THE ANSWER. MMinimum inimizing BBiofilm EEradication C oncentration Concentration www.becscreen.com WHY BIOFILM
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
Surveillance for antimicrobial resistance in enteric bacteria in Australian pigs and chickens
Surveillance for antimicrobial resistance in enteric bacteria in Australian pigs and chickens Dr Pat Mitchell R & I Manager Production Stewardship APL CDC Conference, Melbourne June 2017 Dr Kylie Hewson
PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS
PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis
2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
EARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
Liofilchem. ID-AST systems
Liofilchem ID-AST systems Systems for ID and AST directly from clinical specimens page 1 Integral Systems for ID and AST from isolated colonies page 4 Systems for ID from isolated colonies page 6 Systems
CONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
GENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria
Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Juhee Ahn Department of Medical Biomaterials Engineering Kangwon National University October 23, 27 Antibiotic Development
Short Report. R Boot. Keywords: Bacteria, antimicrobial susceptibility testing, quality, diagnostic laboratories, proficiency testing
Short Report Frequent major errors in antimicrobial susceptibility testing of bacterial strains distributed under the Deutsches Krebsforschungszentrum Quality Assurance Program R Boot Former Section of
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India
ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 731-736 http://www.ijcmas.com Original Research Article Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching
Antibacterial Resistance In Wales
A Report from Public Health Wales Antimicrobial Resistance Programme Surveillance Unit: Antibacterial Resistance In Wales 2005-2013 Authors: Maggie Heginbothom and Robin Howe Version: 1 Antibacterial Resistance
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
Recommendations to take it forward!
Capacity Building and Strengthening of Hospital Infection Control to detect and prevent antimicrobial resistance in India AIIMS-ICMR-CDC EQAS Recommendations to take it forward! Top regional diagnostic
Version 8 January 2009
BSAC Methods for Antimicrobial Susceptibility Testing All enquiries to: Jenny Andrews at: + 44 (0) 121 507 5693 Email: jenny.andrews@swbh.nhs.uk 2 Contents Page Working Party members 5 Abstract 6 Preface
Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
Mongolia September 2012
MICROBIOLOGY: bacterial resistance Roßburg / 9.9.22 MVZ DORTMUND - Dr.Eberhard u. Partner - MICROBIOLOGY bacterial resistance control, role of the laboratory MIKROBIOLOGY www.labmed.de / mikro@labmed.de
EARS-Net Belgium Data call for 2016: Instructions for participating laboratories, including data definition. (version 4, 20/3/2017)
EARS-Net Belgium Data call for 2016: Instructions for participating laboratories, including data definition. (version 4, 20/3/2017) Questions on this document can be directed towards: Karl Mertens Scientific
Antibacterial Resistance In Wales
A Report from Public Health Wales Antimicrobial Resistance Programme Surveillance Unit: Antibacterial Resistance In Wales 2005-2012 Authors: Maggie Heginbothom Robin Howe & Catherine Thomas Version: 1
* gender factor (male=1, female=0.85)
Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12
Quality assurance of antimicrobial susceptibility testing
Quality assurance of antimicrobial susceptibility testing Derek Brown Routine quality control Repeated testing of controls in parallel with tests to ensure that the test system is performing reproducibly
ESCMID Online Lecture Library. by author
Quality Assurance of antimicrobial susceptibility testing Derek Brown EUCAST Scientific Secretary ESCMID Postgraduate Education Course, Linz, 17 September 2014 Quality Assurance The total process by which
Available online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
ANTIMICROBIAL SUSCEPTIBILITY TESTING ON MILK SAMPLES Method and guidelines There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
Should we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
Policy # MI_AST Department of Microbiology. Page Quality Manual
Department of Microbiology Version: 2.0 CURRENT 1 of 160 Prepared by QA Committee Issued by: Laboratory Manager Revision Date: 2/26/2018 Approved by Laboratory Director: Annual Review Date: 5/1/2018 Microbiologist-in-Chief
5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
Michael Hombach*, Guido V. Bloemberg and Erik C. Böttger
J Antimicrob Chemother 2012; 67: 622 632 doi:10.1093/jac/dkr524 Advance Access publication 13 December 2011 Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011